Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00617461
Other study ID # 110527
Secondary ID
Status Completed
Phase Phase 2
First received February 6, 2008
Last updated July 15, 2013
Start date March 2008
Est. completion date July 2009

Study information

Verified date January 2013
Source XenoPort, Inc.
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is evaluate the difference between two doses of gabapentin enacarbil (XP13512/GSK1838262), hereafter referred to as GEn, on pain associated with post-herpetic neuralgia.


Description:

The primary purpose of study PXN110527 was to investigate the efficacy of a high (3600mg/day) dose versus a low (1200mg/day) dose of GEn in subjects with post-herpetic neuralgia (PHN) who have a history of an inadequate response to gabapentin treatment. The study is a cross-over design. Prior to screening subjects are required to have a demonstrated history of an inadequate response (as determined by the investigator) to at least 1800 mg/day of gabapentin. Prior history of treatment with gabapentin includes current treatment at 1800mg/day (2 weeks) or prior treatment with ≥1800mg/day (4 weeks). Subjects could also have been treated with pregabalin monotherapy (150-300mg/day, ≥4 weeks) and had an inadequate response.

Subjects are treated with gabapentin 1800mg/day during the Baseline Period and are randomized if during the Basleline Period they are compliant with gabapentin treatment and have a 24-hour average pain intensity score ≥4.0 based on an 11-point pain intensity numerical rating scale (PI-NRS). Subjects are then randomized to receive gabapentin enacarbil (either 1200mg/day or 3600mg/day in a 1:1 ratio) for Treatment Period 1 (28 days). Followed by a dose of 2400mg/day for 4 days and the alternate fixed dose (either 3600 mg/day or 1200 mg/day) for Treatment Period 2 (28 days).


Recruitment information / eligibility

Status Completed
Enrollment 96
Est. completion date July 2009
Est. primary completion date July 2009
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- 18 years or older

- Documented medical diagnosis of PHN with pain present for at least 3 months from the healing of a herpes zoster rash

- Female subjects are eligible if of non-childbearing potential or not lactating, has a negative pregnancy, and agrees to use one a specified highly effective method for avoiding pregnancy.

- Currently on a stable dose of 1800 mg/day of gabapentin for =2 weeks with inadequate response OR

- Not currently treated with gabapentin, but previously treated with =1800 mg/day of gabapentin for 4 weeks or more with inadequate response.

- Baseline 24-hour average pain intensity score = 4.0 based on an 11-point PI-NRS

- Provides written informed consent in accordance with all applicable regulatory requirements

Exclusion Criteria:

- Other chronic pain conditions not associated with PHN. However, the subject will not be excluded if:

- The pain is located at a different region of the body; and

- The pain intensity is not greater than the pain intensity of the PHN; and

- The subject can assess PHN pain independently of other pain

- Is unable to discontinue prohibited medications or non-drug therapies or procedures throughout the duration of the study

- Hepatic impairment defined as ALT or AST > 2x upper limit of normal (ULN), or alkaline phosphatase or bilirubin > 1.5x ULN

- Chronic hepatitis B or C

- Impaired renal function defined as creatinine clearance <60 mL/min or requiring hemodialysis

- Corrected QT (QTc) interval = 450 msec or QTc interval =480 msec for patients with Bundle Branch Block

- Uncontrolled hypertension at screen (sitting systolic >160 mmHg and/or sitting diastolic >90 mmHg)

- Current diagnosis of active epilepsy or any active seizure disorder requiring chronic therapy with antiepileptic drugs

- Medical condition or disorder that would interfere with the action, absorption, distribution, metabolism, or excretion of GEn, or, in the investigator's judgment

- Is considered to be clinically significant and may pose a safety concern, or,

- Could interfere with the accurate assessment of safety or efficacy, or,

- Could potentially affect a subject's safety or study outcome

- Current or chronic history of liver disease (including acute viral hepatitis), or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).

- Meets criteria defined by the DSM-IV-TR for a major depressive episode or for active significant psychiatric disorders within last year

- Depression in remission, with or without antidepressant treatment, may participate, unless stable antidepressant regimen is a prohibited medication

- Antidepressant medication may not be changed or discontinued to meet entry criteria and must be stable for at least three months prior to enrollment

- History of clinically significant drug or alcohol abuse (DSM-IV-TR) or is unable to refrain from substance abuse throughout the study. Benzodiazepines or atypical benzodiazepines as hypnotic sleep agents permitted.

- Currently participating in another clinical study in which the subject is, or will be exposed to an investigational or non-investigational drug or device

- Has participated in a clinical study and was exposed to investigational or non-investigational drug or device:

- Within preceding month for studies unrelated to PHN, or

- Within preceding six months for studies related to PHN

- Treated previously with GEn

- History of allergic or medically significant adverse reaction to investigational products (including gabapentin) or their excipients, acetaminophen or related compounds

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
GEn 1200mg/day
1200mg/day gabapentin enacarbil
GEn 3600mg/day
3600mg/day gabapentin enacarbil

Locations

Country Name City State
Germany GSK Investigational Site Achim Niedersachsen
Germany GSK Investigational Site Berlin
Germany GSK Investigational Site Berlin
Germany GSK Investigational Site Bochum Nordrhein-Westfalen
Germany GSK Investigational Site Dresden Sachsen
Germany GSK Investigational Site Hattingen Nordrhein-Westfalen
Germany GSK Investigational Site Huettenberg Hessen
Germany GSK Investigational Site Leipzg Sachsen
Germany GSK Investigational Site Mainz Rheinland-Pfalz
Germany GSK Investigational Site Schoenau Baden-Wuerttemberg
Germany GSK Investigational Site Wiesbaden Hessen
United States GSK Investigational Site Austin Texas
United States GSK Investigational Site Bradenton Florida
United States GSK Investigational Site Chicago Illinois
United States GSK Investigational Site Chipley Florida
United States GSK Investigational Site Daytona Beach Florida
United States GSK Investigational Site Decatur Georgia
United States GSK Investigational Site Fort Myers Florida
United States GSK Investigational Site Gainesville Florida
United States GSK Investigational Site Greensboro North Carolina
United States GSK Investigational Site Greensburg Pennsylvania
United States GSK Investigational Site Houston Texas
United States GSK Investigational Site Houston Texas
United States GSK Investigational Site Houston Texas
United States GSK Investigational Site Kansas City Missouri
United States GSK Investigational Site Kingsport Tennessee
United States GSK Investigational Site Lebanon New Hampshire
United States GSK Investigational Site Longview Texas
United States GSK Investigational Site Marianna Florida
United States GSK Investigational Site Marietta Georgia
United States GSK Investigational Site Medford Oregon
United States GSK Investigational Site Miami Springs Florida
United States GSK Investigational Site Missoula Montana
United States GSK Investigational Site Naranja Florida
United States GSK Investigational Site New York New York
United States GSK Investigational Site Norman Oklahoma
United States GSK Investigational Site Oklahoma City Oklahoma
United States GSK Investigational Site Oxnard California
United States GSK Investigational Site Phoenix Arizona
United States GSK Investigational Site Roseville California
United States GSK Investigational Site Salisbury North Carolina
United States GSK Investigational Site San Antonio Texas
United States GSK Investigational Site San Francisco California
United States GSK Investigational Site South Miami Florida
United States GSK Investigational Site St. Louis Missouri
United States GSK Investigational Site Tacoma Washington
United States GSK Investigational Site Tallahassee Florida
United States GSK Investigational Site Tampa Florida
United States GSK Investigational Site Tampa Florida
United States GSK Investigational Site Terre Haute Indiana
United States GSK Investigational Site Weber City Virginia
United States GSK Investigational Site Winston-Salem North Carolina
United States GSK Investigational Site Yakima Washington

Sponsors (1)

Lead Sponsor Collaborator
XenoPort, Inc.

Countries where clinical trial is conducted

United States,  Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Baseline in the Mean 24-hour Average Pain Intensity (API) Score at the Last Week of Each Treatment Period Using Last Observation Carried Forward (LOCF) Data Baseline and end of treatment values are the calculated means of the daily 24-hour API scores for each participant during the last 7 days prior to randomization (baseline) and the last 7 days on treatment within each period (end of treatment). Participants rated their API over the preceding 24 hours, using an 11-point PI-Numerical Rating Scale (0=no pain, 10=pain as bad as you can imagine). LOCF was used if less than 4 days of diary data were provided. Change from baseline was calculated as end of treatment minus baseline. Data are summarized by dose, independent of treatment period. Baseline and End of Treatment (Weeks 4 and 9, representing the last week of each treatment period) No
Primary Change From Baseline in the Mean 24-hour Average Pain Intensity (API) Score at the Last Week of Each Treatment Period Using LOCF Data for Each Treatment Period Baseline and end of treatment values are the calculated means of the daily 24-hour API scores for each participant during the last 7 days prior to randomization (baseline) and the last 7 days on treatment within each period (end of treatment). Participants used a hand-held diary to rate their average pain intensity over the preceding 24 hours, using an 11-point PI-NRS (0=no pain, 10=pain as bad as you can imagine). LOCF was used if less than 4 days of diary data were provided. The by period summary is provided as a sensitivity analysis for the primary analysis. Baseline and End of Treatment (Weeks 4 and 9, representing the last week of each treatment period) No
Secondary Change From Baseline in the Mean Day-time Average Pain Intensity (API) Score at the Last Week of Each Treatment Period Using LOCF Data Day-time is defined as the time between rising in the morning and going to bed at night. Participants recorded day-time API on a daily basis in the evening before bedtime using an 11-point PI-NRS (0=no pain, 10=pain as bad as you can imagine). Baseline and end of treatment scores are as defined for the primary endpoint. Change from baseline is calculated as the end of treatment score minus the baseline score. An ANCOVA with baseline value, BMI, grouped center as covariates was used. Data are summarized by dose, independent of treatment period. Baseline and End of Treatment (Weeks 4 and 9, representing the last week of each treatment period) No
Secondary Change From Baseline in the Mean Day-time Worst Pain Intensity Score at the Last Week of Each Treatment Period Using LOCF Data Day-time worst pain is defined as the participant's assessment of their worst pain intensity between rising in the morning and going to bed at night. Day-time worst pain was recorded in the evening before bedtime using an 11-point PI-NRS (0=no pain, 10=pain as bad as you can imagine). Baseline and end of treatment scores are as defined for the primary endpoint. Change from baseline is calculated as the end of treatment score minus the baseline score. An ANCOVA with baseline value, BMI, grouped center as covariates was used. Data are summarized by dose, independent of treatment period. Baseline and End of Treatment (Weeks 4 and 9, representing the last week of each treatment period) No
Secondary Change From Baseline in the Mean Current (Evening) Pain Intensity Score at the Last Week of Each Treatment Period Using LOCF Data Current pain is defined as the participant's assessment of pain intensity "right now." Participants recorded their current evening pain intensity in the evening before bedtime using an 11-point PI-NRS (0=no pain, 10=pain as bad as you can imagine). Baseline and end of treatment scores are as defined for the primary endpoint. Change from baseline is calculated as the end of treatment score minus the baseline score. An ANCOVA with baseline value, BMI, grouped center as covariates was used. Data are summarized by dose, independent of treatment period. Baseline and End of Treatment (Weeks 4 and 9, representing the last week of each treatment period) No
Secondary Change From Baseline in the Mean Night-time Average Pain Intensity (API) Score at the Last Week of Each Treatment Period Using LOCF Night-time is defined as the time between going to bed in the evening and rising in the morning. Participants recorded night-time API on a daily basis in the morning upon wakening using an 11-point PI-NRS (0=no pain, 10=pain as bad as you can imagine). Baseline and end of treatment scores are as defined for the primary endpoint. Change from baseline is calculated as the end of treatment score minus the baseline score. An ANCOVA with baseline value, BMI, grouped center as covariates was used. Data are summarized by dose, independent of treatment period. Baseline and End of Treatment (Weeks 4 and 9, representing the last week of each treatment period) No
Secondary Change From Baseline in the Mean Night-time Worst Pain Intensity Score at the Last Week of Each Treatment Period Using LOCF Night-time worst pain is defined as the participant's assessment of their worst pain intensity between going to bed and rising in the morning. Participants recorded night-time worst pain in the morning upon wakening using an 11-point PI-NRS (0=no pain, 10=pain as bad as you can imagine). Baseline and end of treatment scores are as defined for primary endpoint. Change from baseline = the end of treatment score minus the baseline score. An ANCOVA with baseline value, BMI, grouped center as covariates was used. Data are summarized by dose, independent of treatment period. Baseline and End of Treatment (Weeks 4 and 9, representing the last week of each treatment period) No
Secondary Change From Baseline in the Mean Current Morning Pain Intensity Score at the Last Week of Each Treatment Period Using LOCF Current pain is defined as the participant's assessment of pain intensity "right now." Participants recorded their current morning pain intensity in the morning upon wakening using an 11-point PI-NRS (0=no pain, 10=pain as bad as you can imagine). Baseline and end of treatment scores are as defined for the primary endpoint. Change from baseline is calculated as the end of treatment score minus the baseline score. An ANCOVA with baseline value, BMI, grouped center as covariates was used. Data are summarized by dose, independent of treatment period. Baseline and End of Treatment (Weeks 4 and 9, representing the last week of each treatment period) No
Secondary Number of Participants Achieving Various Levels of Percent Reduction From Baseline in the Mean 24-hour Average Pain Intensity Score at the Last Week of Each Treatment Period Using LOCF Data Baseline and end of treatment (EOT) scores are the calculated means of the 24-hour average pain scores for each participant during the last 7 days prior to randomization (Baseline) and the 7 days prior to the last on-treatment completed diary (EOT). Percent reduction from baseline was calculated as the [(EOT score minus baseline score) divided by the baseline score], multiplied by 100. The PI-NRS is an 11-point scale (0=no pain, 10=pain as bad as you can imagine) by which a participant assesses their 24-hour average pain intensity. Data are summarized by dose, independent of treatment period. Baseline and End of Treatment (Weeks 4 and 9, representing the last week of each treatment period) No
Secondary Number of Participants Achieving Various Levels of Percent Reduction From Baseline in the Mean 24-hour Average Pain Intensity Score at the Last Week of Each Treatment Period Using LOCF Data by Period Baseline and end of treatment scores are the calculated means of the 24-hour average pain scores for each participant during the last 7 days prior to randomization (Baseline) and the 7 days prior to the last on-treatment completed diary (end of treatment). Percent reduction from baseline was calculated as the [(end of treatment score minus the baseline score) divided by the baseline score], multiplied by 100. The PI-NRS is an 11-point scale (0=no pain, 10=pain as bad as you can imagine) by which a participant assesses their 24-hour average pain intensity. Data are summarized by period. Baseline and End of Treatment (Weeks 4 and 9, representing the last week of each treatment period) No
Secondary Change From Baseline in the Mean Daily Dose in Milligrams of Rescue Medication at the Last Week of Each Treatment Period Mean daily use of rescue medication (milligrams of acetaminophen) was calculated by determining the average number of tablets taken per day of rescue medication (Commercial Tylenol) during treatment and multiplying that by 500 mg. Baseline and end of treatment scores are as defined for the primary endpoint. Change from baseline is calculated as the end of treatment score minus the baseline score. An ANCOVA with baseline value, BMI, grouped center as covariates was used. Data are summarized by dose, independent of treatment period. Baseline and End of Treatment (Weeks 4 and 9, representing the last week of each treatment period) No
Secondary Number of Participants Who Are Responders on the Patient Global Impression of Change (PGIC) at the Last Week of Each Treatment Period Using LOCF Data The PGIC is a single-item questionnaire designed to provide an overall assessment of treatment from the participant's perspective since the start of the study. It is measured on a 7-point scale, where 1=very much improved and 7=very much worse. A participant is considered a responder if they have a response of "very much improved" or "much improved" Data are summarized by dose, independent of treatment period. End of Treatment (Weeks 4 and 9, representing the last week of each treatment period) No
Secondary Number of Participants Who Are Responders on the Patient Global Impression of Change (PGIC) Questionnaire at the Last Week of Each Treatment Period Presented by Period Using LOCF Data The PGIC is a single-item questionnaire designed to provide an overall assessment of treatment from the participant's perspective since the start of the study. It is measured on a 7-point scale, where 1=very much improved and 7=very much worse. A participant is considered a responder if they have a response of "very much improved" or "much improved". Data are summarized by dose within each treatment period. End of Treatment (Weeks 4 and 9, representing the last week of each treatment period) No
Secondary Number of Participants Who Are Responders on the Clinical Global Impression of Change (CGIC) Questionnaire at the Last Week of Each Treatment Period Using LOCF Data The CGIC is a single-item questionnaire designed to provide an overall assessment of treatment from the clinician's perspective since the start of the study. It is measured on a 7-point scale, where 1=very much improved and 7=very much worse. A participant is considered a responder if they have a response of "very much improved" or "much improved." Data are summarized by dose, independent of treatment period. End of Treatment (Weeks 4 and 9, representing the last week of each treatment period) No
Secondary Number of Participants Who Are Responders on the Clinical Global Impression of Change (CGIC) Questionnaire at the Last Week of Each Treatment Period Presented by Period Using LOCF Data The CGIC is a single-item questionnaire designed to provide an overall assessment of treatment from the clinician's perspective since the start of the study. It is measured on a 7-point scale, where 1=very much improved and 7=very much worse. A participant is considered a responder if they have a response of "very much improved" or "much improved." Data are summarized by dose within each treatment period. End of Treatment (Weeks 4 and 9, representing the last week of each treatment period) No
Secondary Change From Baseline in the Mean Sleep Interference Score at the Last Week of Each Treatment Period Using LOCF Data Participants assessed sleep interference due to pain on a daily basis using the 11-point NRS (0=pain does not interfere with sleep, 10=pain completely interferes with sleep). Baseline and end of treatment scores are as defined for the primary endpoint. Change from baseline is calculated as the end of treatment score minus the baseline score. An ANCOVA with baseline value, BMI, grouped center as covariates was used. Data are summarized by dose, independent of treatment period. Baseline and End of Treatment (Weeks 4 and 9, representing the last week of each treatment period) No
Secondary Change From Baseline in the Severity of Pain and the Impact of Pain as Assessed by the Brief Pain Inventory (BPI) at the Last Week of Each Treatment Period Using LOCF The BPI assesses the severity and interference of pain; and consists of 6 items assessed on an 11-point NRS (0=no impact to 10=greatest impact). 2 summary scores are calculated: BPI Severity Score (average of first 4 items) and BPI Interference Score (average of 7 responses to item 6); where scores range from 0 to 10 (0=no impact to 10=greatest impact). Analysis of this endpoint is based on the change from baseline (BL) (EOMT score minus the BL score) using an ANCOVA model with BL value, BMI, grouped center as covariates. Data are summarized by dose, independent of treatment period. Baseline and End of Treatment (Weeks 4 and 9, representing the last week of treatment) No
Secondary Mean Gabapentin Steady-State (ss) Average, Minimum and Maximum Concentrations Steady-state average (Cave, ss), maximum (Cmax, ss), and minimum (Cmin,ss) plasma concentration of gabapentin in each participant were estimated using the gabapentin plasma concentration data and with the aid of a population pharmacokinetic model. Dispersion is represented by the fifth to ninety-fifth percentile, though labeled as "Full Range." A total of 10 blood samples were collected per participant over the Baseline, Period 1, and Period 2 at various timepoints during the dosing interval. Plasma concentration of gabapentin in these samples was measured. A total of 10 blood samples (2 samples at each visit) were collected per participant at Baseline, and the Week 1 and Week 4 visits for each period No
See also
  Status Clinical Trial Phase
Completed NCT02484170 - Mannitol Cream for Post Herpetic Neuralgia Phase 1/Phase 2
Terminated NCT00964990 - A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Patients With Neuropathic Pain (Postherpetic Neuralgia and Post-traumatic Neuralgia) Phase 2
Completed NCT00394901 - A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia Phase 3
Completed NCT01252160 - Safety and Effectiveness of Repeated Administration of QUTENZA Patches for Treatment of Pain Caused by Nerve Damage Phase 4
Completed NCT00377598 - Efficacy, Safety and Tolerability Study of TAK-583 in Subjects With Postherpetic Neuralgia Phase 2/Phase 3
Completed NCT00160667 - A Study Assessing Efficacy of Brivaracetam in Subjects With Persistent Pain After Shingles (Post-herpetic Neuralgia) Phase 2
Terminated NCT00245544 - Safety and Preliminary Efficacy of MK0759 in Postherpetic Neuralgia (PHN)(0759-004) Phase 2
Completed NCT00335933 - Safety and Efficacy of Gabapentin in Postherpetic Neuralgia Phase 3
Withdrawn NCT02426411 - Dose Ranging Trial to Determine the Safety and Efficacy of EMA401 in Patients With PHN Phase 2
Completed NCT01129531 - A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic Neuralgia Phase 2
Completed NCT00674687 - A Study Of The Efficacy Of Gabapentin In Neuropathic Pain Patients As Measured By Quantitative Sensory Testing N/A
Terminated NCT01678924 - A Safety and Efficacy Study of AGN-214868 in Patients With Postherpetic Neuralgia Phase 2
Completed NCT00424372 - A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin For Postherpetic Neuralgia Phase 3
Completed NCT00619476 - A Study In Patients With Neuropathic Pain From Post-Herpetic Neuralgia (PHN) Phase 2
Terminated NCT00295776 - Lamictal in the Treatment of Post-Herpetic Neuralgia Phase 2/Phase 3
Completed NCT00570310 - Neuropathic Pain Syndrome Patient Study (MK-0000-072) Phase 1
Terminated NCT00282763 - A Research Study to Evaluate the Safety and Effectiveness of MK0686 for the Treatment of Postherpetic Neuralgia (Also Known as PHN or Post Shingles Pain) (0686-005) Phase 2
Completed NCT00568321 - RN624 For Pain Of Post-Herpetic Neuralgia Phase 2
Not yet recruiting NCT01102101 - Effect of Opioids in Neuropathic Pain in Postherpetic Patients Phase 3
Completed NCT00614705 - PH-797804 Versus Placebo For The Treatment Of Neuropathic Pain Associated With Post-Herpetic Neuralgia Phase 2